The new cystic fibrosis triplet from Vertex ranks as the single most valuable late-stage therapy in the global pipeline, according to a new report from Vantage, the editorial arm of Evaluate. And they are way out ahead on the net present value scale used to rank these would-be blockbusters.
In this ranking, which you can see in full below, the Vertex triplet including VX-659 has a net present value — or NPV — of $14.4 billion as Phase III data loom, calculating costs and potential revenue.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription